Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia

Megan Othus, PhD, Brent L. Wood, MD PhD, Elihu H. Estey, MD, Stephen Petersdorf, MD, Frederick R. Appelbaum, MD, Harry P Erba, MD PhD, Roland B. Walter, MD PhD MS

Blood (2015) 126 (23): 2569.

https://doi.org/10.1182/blood.V126.23.2569.2569

Published: 2015

Journal Articles

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report

Fabiana Ostronoff, Megan Othus, Robert B. Gerbing, Michael R. Loken, Susana C. Raimondi, Betsy A. Hirsch, Beverly J. Lange, Stephen Petersdorf, Jerald Radich, Frederick R. Appelbaum, Alan S. Gamis, Todd A. Alonzo, Soheil Meshinchi

Blood (2014) 124 (15): 2400–2407.

https://doi.org/10.1182/blood-2014-04-570929

Published: 2014

Includes: Supplemental data

Journal Articles

Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic

Megan Othus, PhD, Mukherjee Sudipto, MD, Mikkael A. Sekeres, MD, MS, John Godwin, MD, Jeanne E. Anderson, MD, Stephen Petersdorf, MD, Frederick R. Appelbaum, MD, Harry P Erba, MD, Elihu H. Estey, MD

Blood (2013) 122 (21): 3924.

https://doi.org/10.1182/blood.V122.21.3924.3924

Published: 2013

Journal Articles

Evaluation Of Which Patients Get a Second Course Of 3+7 On Cooperative Group Trials For Newly Diagnosed Acute Myeloid Leukemia: A Report From SWOG

Megan Othus, Phd, Frederick R. Appelbaum, MD, Stephen Petersdorf, MD, Harry P Erba, MD, Elihu H. Estey, MD

Blood (2013) 122 (21): 3925.

https://doi.org/10.1182/blood.V122.21.3925.3925

Published: 2013

Journal Articles

Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report

Farhad Ravandi, MD, Megan Othus, PhD, Stefan H. Faderl, MD, Derek L. Stirewalt, MD, Sherry R. Pierce, RN, BS, Gautam Borthakur, MD, John Godwin, MD, Jeanne E. Anderson, MD, Stephen Petersdorf, MD, Jorge E. Cortes, MD, Fabiana Ostronoff, MD, Era Pogosova-Agadijanyan, MD, Frederick R. Appelbaum, MD, Hagop M. Kantarjian, MD, Elihu H. Estey, MD

Blood (2013) 122 (21): 2686.

https://doi.org/10.1182/blood.V122.21.2686.2686

Published: 2013

Journal Articles

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

Fabiana Ostronoff, MD, Megan Othus, PhD, Soheil Meshinchi, MD, PhD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Alan List, MD, Vivian G. Oehler, MD, Stephen Petersdorf, MD, Era L. Pogosova-Agadjanyan, Jerald Radich, MD, Cheryl L. Willman, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD

Blood (2013) 122 (21): 1315.

https://doi.org/10.1182/blood.V122.21.1315.1315

Published: 2013

Journal Articles

The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials

Robert K. Hills, MA, MSc, DPhil, Stephen Petersdorf, MD, Elihu H. Estey, MD, Megan Othus, PhD, Frederick R. Appelbaum, MD, Sylvie Castaigne, Herve Dombret, MD, PhD, Sylvie Chevret, Jacques Delaunay, MD, Norbert Ifrah, Jean-Yves Cahn, MD, PhD, Christian Recher, MD, Alan K Burnett, MD

Blood (2013) 122 (21): 356.

https://doi.org/10.1182/blood.V122.21.356.356

Published: 2013

Journal Articles

NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children’s Oncology Group and SWOG

Fabiana Ostronoff, MD, Megan Othus, PhD, Robert B. Gerbing, MA, Michael R. Loken, PhD, Susana C Raimondi, PhD, Betsy A. Hirsch, PhD, Beverly J. Lange, MD, Stephen Petersdorf, MD, Jerald Radich, MD, Frederick R. Appelbaum, MD, Alan S. Gamis, MD, MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD

Blood (2013) 122 (21): 488.

https://doi.org/10.1182/blood.V122.21.488.488

Published: 2013

Journal Articles

Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA)

Megan Othus, PhD, Hagop M. Kantarjian, MD, Stephen Petersdorf, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Sherry A. Pierce, RN, BS, Harry Paul Erba, MD, PhD, Stefan Faderl, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 129.

https://doi.org/10.1182/blood.V120.21.129.129

Published: 2012

Journal Articles

NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML)

Joshua R. Veatch, MD, PhD, Ravinder K Sandhu, MD, Kathleen Shannon-Dorcy, RN, John M. Pagel, MD, PhD, Pamela S. Becker, MD, PhD, Stephen Petersdorf, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 1479.

https://doi.org/10.1182/blood.V120.21.1479.1479

Published: 2012

Journal Articles

Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

Pamela S. Becker, MD, PhD, Bruno C. Medeiros, MD, Anthony Selwyn Stein, M.D., Frederick R. Appelbaum, MD, Bart L Scott, MD, MS, Colleen Delaney, MD, MSc, Megan Othus, PhD, Paul C. Hendrie, MD, PhD, Kelda M. Gardner, PA-C, Stephen Petersdorf, MD, John M. Pagel, MD, PhD, Roland B. Walter, MD, PhD, Cynthia Parks, Elihu H. Estey, MD

Blood (2012) 120 (21): 3594.

https://doi.org/10.1182/blood.V120.21.3594.3594

Published: 2012

Journal Articles

A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.

Blood (2012) 120 (21): 2590.

https://doi.org/10.1182/blood.V120.21.2590.2590

Published: 2012

Journal Articles

Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia.

Daniel DeAngelo, MD, Wendy Stock, MD, Stephen Petersdorf, MD, Shaw-Ling Wang, Angela Volkert, Erik Vandendries, Anjali Advani, MD

Blood (2012) 120 (21): 2612.

https://doi.org/10.1182/blood.V120.21.2612.2612

Published: 2012

Journal Articles

Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG

Era L. Pogosova-Agadjanyan, Kenneth J. Kopecky, PhD, Stephen Petersdorf, MD, Harry Paul Erba, MD, PhD, Richard M. Stone, MD, Soheil Meshinchi, MD, PhD, Thomas J. Nevill, MD, FRCPC, Jerald P. Radich, MD, Leif Stenke, MD, PhD, Marilyn L Slovak, PhD, Robert K Stuart, MD, Martin S. Tallman, MD, Cheryl L Willman, MD, Rebecca M. Mortensen, Breanna L. Wentz, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD

Blood (2011) 118 (21): 2520.

https://doi.org/10.1182/blood.V118.21.2520.2520

Published: 2011

Journal Articles

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

Mikkael A. Sekeres, Holly Gundacker, Jeffrey Lancet, Anjali Advani, Stephen Petersdorf, Jane Liesveld, Deborah Mulford, Tom Norwood, Cheryl L. Willman, Frederick R. Appelbaum, Alan F. List

Blood (2011) 118 (3): 523–528.

https://doi.org/10.1182/blood-2011-02-337303

Published: 2011

Journal Articles

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Blood (2011) 117 (12): 3294–3301.

https://doi.org/10.1182/blood-2010-08-301796

Published: 2011

Journal Articles

A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605)

Mikkael A. Sekeres, MD, MS, Holly Gundacker, Jeffrey Lancet, MD, Anjali Advani, MD, Stephen Petersdorf, Jane L. Liesveld, MD, Deborah Mulford, Tom Norwood, Cheryl L. Willman, MD, Alan F. List, Frederick R. Appelbaum, MD

Blood (2010) 116 (21): 332.

https://doi.org/10.1182/blood.V116.21.332.332

Published: 2010

Journal Articles

Prognostic Factors On Outcome of Mantle Cell Lymphoma Patients Relapsing After Autologous Hematopoietic Stem Cell Transplantation.

Lihua E. Budde, MD, PhD, Katherine A Guthrie, PhD, Brian G. Till, MD, Thomas Chauncey, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD, Stephen Petersdorf, William Bensinger, MD, Leona Holmberg, MD, PhD, Andrei R. Shustov, MD, David G Maloney, Ajay K. Gopal, MD

Blood (2009) 114 (22): 3327.

https://doi.org/10.1182/blood.V114.22.3327.3327

Published: 2009

Journal Articles

Frequency of Allogeneic Stem Cell Transplant(SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage Therapy.

Ravinder Sandhu, MD, Stephen Petersdorf, MD, Brenda M. Sandmaier, MD, Paul O'Donnell, MD, PhD, Pamela S. Becker, MD, PhD, H. Joachim Deeg, MD, Frederick R Appelbaum, MD, Elihu H. Estey, MD

Blood (2009) 114 (22): 4332.

https://doi.org/10.1182/blood.V114.22.4332.4332

Published: 2009

Journal Articles

Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.

Blood (2009) 114 (22): 788.

https://doi.org/10.1182/blood.V114.22.788.788

Published: 2009

NARROW

Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report

Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic

Evaluation Of Which Patients Get a Second Course Of 3+7 On Cooperative Group Trials For Newly Diagnosed Acute Myeloid Leukemia: A Report From SWOG

Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials

NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children’s Oncology Group and SWOG

Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA)

NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML)

Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.

Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia.

Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605)

Prognostic Factors On Outcome of Mantle Cell Lymphoma Patients Relapsing After Autologous Hematopoietic Stem Cell Transplantation.

Frequency of Allogeneic Stem Cell Transplant(SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage Therapy.

Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only